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Fecal microbiota and bile acid interactions 
with systemic and adipose tissue metabolism 
in diet-induced weight loss of obese 
postmenopausal women
José O. Alemán1,2*, Nicholas A. Bokulich3, Jonathan R. Swann4, Jeanne M. Walker1, Joel Correa De Rosa1, 
Thomas Battaglia2, Adele Costabile5, Alexandros Pechlivanis4, Yupu Liang1, Jan L. Breslow1, Martin J. Blaser2 
and Peter R. Holt1
Abstract 
Background: Microbiota and bile acids in the gastrointestinal tract profoundly alter systemic metabolic processes. 
In obese subjects, gradual weight loss ameliorates adipose tissue inflammation and related systemic changes. We 
assessed how rapid weight loss due to a very low calorie diet (VLCD) affects the fecal microbiome and fecal bile acid 
composition, and their interactions with the plasma metabolome and subcutaneous adipose tissue inflammation in 
obesity.
Methods: We performed a prospective cohort study of VLCD-induced weight loss of 10% in ten grades 2–3 obese 
postmenopausal women in a metabolic unit. Baseline and post weight loss evaluation included fasting plasma 
analyzed by mass spectrometry, adipose tissue transcription by RNA sequencing, stool 16S rRNA sequencing for fecal 
microbiota, fecal bile acids by mass spectrometry, and urinary metabolic phenotyping by 1H-NMR spectroscopy. Out-
come measures included mixed model correlations between changes in fecal microbiota and bile acid composition 
with changes in plasma metabolite and adipose tissue gene expression pathways.
Results: Alterations in the urinary metabolic phenotype following VLCD-induced weight loss were consistent with 
starvation ketosis, protein sparing, and disruptions to the functional status of the gut microbiota. We show that the 
core microbiome was preserved during VLCD-induced weight loss, but with changes in several groups of bacterial 
taxa with functional implications. UniFrac analysis showed overall parallel shifts in community structure, correspond-
ing to reduced abundance of the genus Roseburia and increased Christensenellaceae;g__ (unknown genus). Imputed 
microbial functions showed changes in fat and carbohydrate metabolism. A significant fall in fecal total bile acid 
concentration and reduced deconjugation and 7-α-dihydroxylation were accompanied by significant changes in 
several bacterial taxa. Individual bile acids in feces correlated with amino acid, purine, and lipid metabolic pathways in 
plasma. Furthermore, several fecal bile acids and bacterial species correlated with altered gene expression pathways 
in adipose tissue.
Conclusions: VLCD dietary intervention in obese women changed the composition of several fecal microbial popu-
lations while preserving the core fecal microbiome. Changes in individual microbial taxa and their functions corre-
lated with variations in the plasma metabolome, fecal bile acid composition, and adipose tissue transcriptome.
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Background
The fecal microbiome has emerged as a potential area of 
research to address the obesity epidemic in the developed 
world [1–4]. Dietary manipulations for weight reduc-
tion that emphasize differing macro nutrient composi-
tion generally have failed to cause sustained weight loss, 
instead leading to large but temporary changes in micro-
biota composition [5]. Caloric restriction by medical or 
surgical measures is successful in lowering weight and 
modulating or eliminating several obesity complications 
such as type 2 diabetes, hepatic steatosis and cardiovas-
cular disease [6, 7]. Rapid weight loss using a very low 
calorie diet (VLCD) is effective in short term studies or 
to prepare morbidly obese subjects for bariatric surgery 
[8]. These diets typically are very low in carbohydrate and 
fat content while keeping protein content optimal.
We recently completed a study providing a VLCD 
fed to ten class 2–3 obese post-menopausal women 
(BMI > 35 kg/m2) in the metabolic facilities of the Rock-
efeller University Hospital to achieve rapid weight loss 
of 10% of baseline weight in a mean of 46 days [9]. This 
intervention reduced circulating leukocytes, high-sen-
sitivity C-reactive protein (hsCRP), as well as IL6 and 
improved insulin sensitivity. A surprising finding was 
an increase in subcutaneous adipose tissue crown-like 
structures (CLS) not accompanied by change in inflam-
matory gene expression, but associated with increased 
circulating fatty acids, glycerol, and ketone bodies indica-
tive of rapid lipolysis. We suggested that this was part of 
an adipose tissue remodeling process. Numerous fasting 
plasma metabolites were significantly altered after weight 
loss. As part of that study, we collected fresh fecal sam-
ples for analyses of microbiota and bile acids at baseline 
and after the planned weight loss had been achieved.
Obese individuals have been reported to have different 
microbial richness and composition than normal weight 
individuals [10], and their gut microbiota may harvest 
more calories from the diet [11]. The metabolic changes 
of obesity may be accompanied by altered gastrointesti-
nal microbiota [12–14] and fecal excretion of differing 
bile acids [15]. Furthermore, weight loss by medical [16] 
or surgical means [17] profoundly affects bile acid home-
ostasis as well as fecal microbiota and short chain fatty 
acid composition. Gut microbiota appear to have a major 
effect on circulating metabolites [18] and thus can affect 
caloric utilization through gut-brain interactions [13, 14]. 
The concentration and composition of bile acids in the 
gastrointestinal track also affect carbohydrate and lipid 
metabolism and may play a role in altering rates of weight 
loss [19].
The microbiota and bile acids present in the gut lumen 
have profound roles in determining systemic metabo-
lism [20, 21]. Although changes in fecal microbiota have 
been correlated with plasma metabolites in obesity and 
weight loss [18, 22], the interactions of microbiota and 
bile acids in the gut lumen with circulating metabolites 
and adipose tissue metabolism in humans are unknown. 
In the current study, we examined the effects of VLCD-
induced 10% weight loss in obese women upon fecal 
microbiota and bile acid content and composition. We 
hypothesized that VLCD-induced weight loss would 
have a modest but measureable effect on fecal microbiota 
with associated changes in fecal bile acids in response to 
nutrient restriction. We further investigated the interre-
lationship between changes in fecal microbiota and fecal 
bile acids, as well as the effects on circulating metabo-
lites and subcutaneous adipose tissue. Following VLCD-
induced weight loss, we found linked changes in the fecal 
microbiome, plasma metabolome, and adipose tissue 
transcriptome.
Methods
The details of this clinical study have been published [9]. 
In brief, eligible subjects were obese (with a BMI ≥ 35 
at the time of screening) postmenopausal women. Sub-
jects who had clinical cardiovascular disease (CVD); had 
type 2 diabetes; were on oral hypoglycemic agents; were 
smokers; were regular users of aspirin, fish oils or vitamin 
D supplements; had a history of gastrointestinal surgery 
other than appendectomy; or had cancer were excluded. 
Subjects with antibiotic use within 3  months or during 
the study were excluded. Of 12 subjects enrolled, 10 com-
pleted the study. In this single center study performed 
at The Rockefeller University Hospital, subjects under-
went a complete medical examination, standard blood 
and urine tests, and an electrocardiogram; all were found 
to be healthy. The sample size for the original study [9] 
Trial Registration ClinicalTrials.gov NCT01699906, 4-Oct-2012, Retrospectively registered. URL-https ://clini caltr ials.gov/
ct2/show/NCT01 69990 6
Keywords: Obesity, Diet-induced weight loss, Plasma metabolome, Fecal microbiota, Fecal bile acids, Correlation 
analysis, Gut microbiota-fecal bile acids, Gut microbiota-plasma metabolome, Fecal bile acids-plasma metabolome, 
Fecal microbiota-adipose tissue transcriptome
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was derived to determine whether loss of 10% of baseline 
weight would significantly change the density of CLS in 
adipose tissue, but was also influenced by logistical and 
feasibility considerations.
Trial approval and registration
The study was approved by the Institutional Review 
Boards at Rockefeller University, Weill Cornell Medi-
cal College, and Memorial Sloan Kettering Cancer 
Center, and registered under ClinicalTrials.gov identifier 
NCT01699906.
Interventions
Participants were admitted to the Rockefeller University 
Hospital for baseline testing and underwent an initial 
3-day dietary adjustment period during which they con-
sumed 50% of their calculated caloric intake based on 
their pre-study diet assessment followed by the 800 kcal/
day VLCD. After losing approximately 10% of their base-
line body weight, subjects continued to consume the 
VLCD for 3 days, when all of the baseline measurements 
were repeated.
The VLCD consisted of a commercially available diet 
(New Direction Program Robard Corporation, Mount 
Laurel NJ) that provided approximately 800 kcal/day with 
an estimated macronutrient energy distribution of 54% 
protein, 26% carbohydrate, 20% fat [23]. This commercial 
preparation provided a choice of shakes, soups, bars, and 
puddings. Subjects had 4 meal choices per day and con-
sumed one item every 4 waking hours.
Baseline and final testing procedures
Fasting blood samples were analyzed in the Clinical 
Pathology Laboratory of the Memorial Sloan Ketter-
ing Cancer Center for electrolytes, liver function, renal 
function, lipid profile, and hsCRP. Body composition 
was measured using the BodPod Tracking system based 
on air displacement plethysmography (COSMED, Italy). 
Subcutaneous aspiration adipose tissue biopsies were 
performed and were frozen in RNA later for subsequent 
RNA extraction and analysis. A baseline stool sample 
was collected within the first 2 days after admission and 
a final sample taken during the last 3  days of the final 
evaluation. Immediately after collection, the stool sam-
ples were snap-frozen and kept at − 80 °C until analysis. 
Plasma FGF19 levels were measured by ELISA (R&D 
systems, Minneapolis MN) following the manufacturer’s 
instructions.
Statistical analyses
Two-tailed paired t-tests and Wilcoxon tests were used 
to compare anthropometric measurements, biochemical 
variables, serum cytokines, and immunohistochemi-
cal values before and after VLCD-induced weight loss, 
with p < 0.05 considered significant. GraphPad Prism and 
Excel were used for data visualization. Statistical analyses 
for the individual methods are described below.
Fecal microbiome analyses
Fecal samples were collected and snap-frozen and DNA 
prepared using a phenol–chloroform extraction tech-
nique with bead beating for mechanical disruption. Puri-
fied DNA was PCR-amplified using modified universal 
primers for the V4–V5 portion of the 16S ribosomal 
RNA gene, per Additional file  1: Table  S1. The purified 
PCR products were pooled and barcoded following the 
Illumina TruSeq Sample Preparation protocol and exam-
ined using the Illumina MiSeq sequencing platform.
Microbiome sequencing data were analyzed with 
QIIME2 2017.2 (https ://qiime 2.org), a plugin-based 
microbiome analysis platform [24]. Raw sequence 
data were demultiplexed and quality filtered using the 
q2-demux plugin. This was followed by denoising with 
DADA2 [25] with the q2-dada2 plugin for quality filter-
ing and identification of sequence variants (i.e., 100% 
operational taxonomic units). Sequence variants were 
aligned with mafft [26] (using the q2-alignment plugin) 
and used to construct a phylogeny with fasttree2 [27] 
(using the q2-phylogeny plugin). Alpha-(observed 
OTUs, Faith’s Phylogenetic Diversity [28]) and beta-
diversity metrics (weighted and unweighted UniFrac 
[29]) and principal coordinate analysis (PCoA) were cal-
culated using the q2-diversity plugin at a depth of 8000 
sequences per sample. Paired difference testing between 
pre- and post-VLCD groups was performed with the 
q2-longitudinal plugin [30]. Sequence variants were tax-
onomically classified using classify-sklearn [31] against 
the Greengenes 13_8 99% OTUs reference sequences 
[32]. All downstream analyses of taxonomic composi-
tion were performed at genus level. We used paired Wil-
coxon signed rank tests to determine whether the relative 
abundances of individual microbial taxa differed between 
paired baseline and post-VLCD time points within indi-
vidual subjects. PERMANOVA tests with 999 permuta-
tions were used to determine whether between-sample 
distances were significantly different between pre- and 
post-VLCD groups and between subjects [33]. Total bac-
terial count was measured by PCR of bacterial 16S rRNA 
gene sequences as previously described [34].
Metabolomic analyses
Plasma metabolomics by mass spectrometry
Plasma samples were analyzed using a commer-
cially available platform (Metabolon, Durham NC) for 
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detection of biochemicals of known identity using liq-
uid chromatography–mass spectrometry (LC–MS) and 
gas chromatography–mass spectrometry (GC–MS). 
Matched paired t-tests were used to identify com-
pounds that differed significantly between the pre- 
and post-weight loss samples correcting for multiple 
measurements.
Urinary metabolomics by 1H NMR spectroscopy
Urine metabolic phenotypes were measured by 1H NMR 
spectroscopy using a 700  MHz Bruker NMR spectrom-
eter, operating at 300  K and equipped with a 5  mm 
1H(13C/15N) inverse cryoprobe. All samples were pre-
pared using methods as described [35]. For each urine 
sample, a standard one-dimensional NMR spectrum was 
acquired with water peak suppression using a standard 
pulse sequence. For each spectrum, 8 dummy transients 
and 128 transients were collected into 64  K data points 
with a spectral width of 12.001 ppm, and all spectra were 
manually corrected for phase and baseline distortions. 
Urine samples were referenced to the TSP singlet at δ 0.0. 
An in-house Matlab (version R2009b, The Mathworks, 
Inc.; Natwick MA) script was used to digitize the spectra. 
The region containing the water resonance was removed 
from the spectra to minimize the baseline distortions 
resulting from imperfect water saturation.
Intervention-associated metabolic variation was inves-
tigated in the urinary metabolic profile using orthogo-
nal projection to latent structures-discriminant analysis 
(OPLS-DA) constructed using unit variance scaling using 
in-house Matlab scripts. 1H NMR spectroscopic profiles 
were used as the descriptor matrix (X) and class mem-
bership (sampling point: pre = 0, post-intervention = 1) 
as the dummy matrix (Y). Loading coefficient plots were 
generated by back-scaling transformation to display the 
covariance between the Y-response matrix (pre/post-
intervention) and the signal intensity of the metabolites 
in the NMR data (X). Hence, the direction and magnitude 
of the signals relate to the covariation of the metabolites 
with the Y-response in the model. Colors projected onto 
the coefficient plot indicate the correlation coefficient  (r2) 
between each metabolite and the Y-response variable, 
with red indicating strong significance and blue indicat-
ing weak significance. The predictive performance  (Q2Y) 
of the model was calculated using a sevenfold cross vali-
dation approach and model validity was established by 
permutation testing (10,000 permutations), with results 
given as p values.
Fecal bile acid measurements by ultra performance liquid 
chromatography–mass spectrometry (UPLC–MS)
Fecal samples were prepared by combining 100  mg of 
dried feces with 2  mL of NaOH (0.1  mol/L) and then 
incubating at 60 °C for 1 h. Water (4 mL) was then added 
to the samples followed by homogenization using a Pol-
ytron homogenizer (Kinematica GMBH, Lucerne, Swit-
zerland) set at maximal speed for 30  s. Samples were 
spun at 20,000×g for 20  min and the supernatant was 
removed. Bile acids were measured in the supernatant as 
described [36], using ACQUITY ultra performance liq-
uid-chromatography (UPLC) (Waters Ltd., Elstree, UK) 
coupled to a Xevo G2 Q-ToF mass spectrometer (Waters, 
Manchester, UK) equipped with an electrospray ioni-
zation source operating in negative mode. TargetLynx 
application manager, a module of the MassLynx software, 
was used for the processing and quantification of the 
results. In total, 25 bile acids were quantified in the fecal 
samples using the method created from the retention 
times and mass spectra acquired from authentic standard 
solutions, analyzed in the same conditions as the sam-
ples. Results are presented as mass spectrometry counts 
or ratio from post weight loss (PostWL)/preweight loss 
(PreWL) samples.
Pairwise correlation analyses statistics
Plasma metabolites that were significantly changed 
from pre- to post-weight loss (paired t test corrected 
for multiple comparisons p < 0.05) were included. Bacte-
rial taxa were filtered by significant change from pre- to 
post-weight loss with a magnitude of change > 30% from 
pre- to post-weight loss. Fecal bile acids that were sig-
nificantly changed from the pre- to post-weight loss were 
included in this analysis (paired t-test with Tukey’s cor-
rection p < 0.05). Pairwise correlation analyses between 
plasma metabolites and fecal bacterial taxa, fecal bile 
acids and fecal bacterial taxa, plasma metabolites and 
fecal bile acids, adipose tissue transcriptome and fecal 
bile acids, adipose tissue transcriptome and fecal bacte-
rial taxa were carried out by cross-product correlation 
and displayed as a heatmap using R. We outline the anal-
yses presented in this study in Fig. 1. A correlogram was 
constructed for each binary dataset comparison in R to 
display the correlation matrix calculated using Spearman 
correlation p-value < 0.1 corrected for multiple testing. 
For every pairwise comparison (e.g. bile acids and bac-
terial taxa), positive correlations (p < 0.1) are indicated 
by red and negative correlations by blue, while strongly 
positive associations (p < 0.05) are denoted with dark red 
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and strongly negative associations are denoted with dark 
blue. Bubble plots were used to display the magnitude of 
the correlation (r-value) against the significance of such 
correlation (p-value) for a given feature or feature set.
Results
The detailed description of the clinical, plasma metabo-
lome, and adipose tissue transcriptome results of this 
study have been reported [9]. Summarizing these prior 
results, the VLCD, low in carbohydrate and fat con-
tent but with adequate protein content, induced ~ 10% 
weight loss in a mean of 46.2 ± 15.3 days. Most (85%) of 
the weight loss was fat, with the remainder of weight lost 
being water and lean protein. Weight loss was accom-
panied by improved insulin sensitivity, a pronounced 
fall in serum leptin, and decreased WBC and hsCRP, 
but circulating uric acid levels did not change signifi-
cantly (PreWL 6.2 ± 0.2, PostWL 5.9 ± 0.4 p = 0.29). In 
adipose tissue, CLS density increased without concomi-
tant changes in adipocyte diameter or in inflammatory 
gene expression pathways. However, the expression of 
gene pathways involved in fatty acid and phospholipid 
metabolism increased with parallel decreases in fatty 
acid synthesis gene expression. In addition, of 336 plasma 
metabolites detected, 131 changed significantly, with 67 
increasing and 64 decreasing during weight loss. This 
included increased levels of glycerol and ketones such as 
β-hydroxybutyrate (BHB) (16-fold increase), consistent 
with starvation ketosis.
Newly reported in this manuscript, several metabolic 
changes were detected by urinary metabolic phenotypes 
before and after VLCD-induced weight loss using 1H 
NMR spectroscopy (Additional file  1: Fig.  S1). The par-
tial least squares-discriminant analysis (PLS-DA) model 
comparing the metabolic profiles between the sampling 
points had strong predictive power  (Q2Y = 0.56; p ≤ 001), 
indicating clear metabolic differences following weight 
loss. Consistent with the plasma data, urine concentra-
tions of acetoacetate and acetone were increased post-
VLCD, consistent with starvation ketosis. 3-Methyl 
histidine and creatine, metabolites related to muscle pro-
tein catabolism, decreased following the VLCD, sugges-
tive of protein-sparing. Alanine and taurine also showed 
diminished excretion. The amino acid isoleucine and its 
breakdown products 3-methyl-2-oxovalerate 3-hydrox-
yisovalerate increased in urine after VLCD-induced 
weight loss. Microbial derived co-metabolites of tyros-
ine and phenylalanine, 4-cresyl sulfate (4CS) and pheny-
lacetylglutamine (PAG), increased in the urine whereas 
the microbial co-metabolite of choline, trimethylamine-
N-oxide (TMAO), decreased. Lower urinary TMAO may 
reflect a lower intake of choline, consistent with reduced 
excretion of the endogenous choline metabolite, dimeth-
ylglycine (DMG). The urinary excretion of metabolites 
was altered post weight loss with increased excretion 
of lactate and the TCA cycle intermediates, citrate and 
succinate.
Effects of the VLCD‑induced weight loss on the fecal 
microbiome
The VLCD led to no overall changes in total microbiota 
diversity or bacterial count by PCR, but caused spe-
cific and potentially metabolically significant changes 
in a number of species. Given the possible relationships 
between the intestinal microbiome and metabolic states 
[11, 12], we examined the effects of the VLCD-induced 
weight loss upon the fecal microbiome. Mean total fecal 
bacterial DNA content was unaffected by the interven-
tion (PreWL 1.23 ± 0.24 × 108, post WL 1.40 ± 0.33 × 108 
16S rRNA copies/mg feces, p = 0.64). The overall alpha 
Fecal Microbiome Plasma MetabolitesAdipose Tissue Transcriptome
Fecal Bile Acids
Clinical Data 
Fig 4B
Fig 5B
Fig 6A
Fig 7B
Fig 7A
Fig. 1 Outline of pairwise correlation analyses performed
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diversity of the fecal microbiome, calculated as observed 
sequence variants; Faith’s phylogenetic diversity; and 
Shannon Index were also unchanged (paired t-test 
p > 0.05).
The 20 most abundant taxa in the fecal microbiota 
analysis comprise 91.3% of the PreWL sequences and 
89.9% of the PostWL sequences. Plotting the 20 most 
abundant fecal taxa revealed marked heterogeneity 
between subjects, but substantial similarity between 
pre- and post-WL samples within each subject (Fig.  2). 
Several patterns were discernible. The inter-personal var-
iation is greater than the variation due to treatment. Wil-
coxon testing showed that the relative abundance of the 
genus Roseburia fell with the VLCD-induced weight loss 
(PreWL 0.070 ± 0.027, post WL 0.005 ± 0.003, p = 0.001), 
whereas Christensenellaceae;g__ (unknown genus) rose 
(PreWL 0.005 ± 0.003, post WL 0.017 ± 0.007, p = 0.032). 
Although taxa Akkermansia and Streptococcaceae;g__ as 
a proportion of total microbiota were quite low, a bloom 
of Akkermansia was found in the PostWL specimen from 
subject 4 and of Streptococcaceae;g__ in the PostWL 
specimen in Subject 6. The ratio of Bacteroidetes to Fir-
micutes did not change significantly (PreWL 0.06 ± 0.07 
versus PostWL 0.07 ± 0.0.05, p = NS) despite the sus-
tained weight loss.
The effect of the intervention on the community struc-
ture of the fecal microbiota was analyzed by unweighted 
and weighted UniFrac analysis, which assesses the degree 
of phylogenetic similarity among fecal samples, and was 
visualized by PCoA. In unweighted UniFrac analysis, three 
Subject
1  2 3  4   5  6  7  8  9  10
Fig. 2 VLCD-induced weight loss modulates the fecal microbiome. Fecal samples were collected pre- and post-weight loss, 16S rRNA gene 
abundance determined via the MiSeq platform, and analyzed using QIIME 2. Microbial composition detected before and after the VLCD for the 
20 most abundant taxa. The color key indicates specific bacterial taxa. All taxonomic analyses were performed at genus level, but some of the 
sequences detected were classified to groups with ambiguous genus-level names. Hence, Clostridiaceae does not actually indicate all members of 
the family Clostridiaceae, but rather all sequences classified as Clostridiaceae;g__ (i.e., family Clostridiaceae but unknown genus)
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principal coordinates (PCs) account for 48% of the vari-
ability (Fig. 3a). The greatest differences between the indi-
vidual study subjects were captured by PC1. The effects of 
the VLCD weight loss regimen were chiefly captured along 
PC2. Across all subjects, there was a consistent shift along 
PC2 when comparing pre- to post-WL samples (paired 
t-test, p < 0.001), indicating parallel shifts in community 
composition. This was also observed with weighted Uni-
Frac analysis (paired t-test, p < 0.0002) (data not shown). 
Mean unweighted UniFrac distances were significantly 
lower within subjects versus between subjects (Fig. 3b), as 
represented by the PCoA results. There was no consistent 
shift in beta-diversity between the PreWL- and PostWL 
groups (PERMANOVA p > 0.05).
PICRUSt-imputed microbial functional analysis (Fig. 3c) 
showed relative enrichment of bacterial genes involved in 
fatty acid biosynthesis and glycerolipid metabolism, as well 
as pyruvate and pentose phosphate metabolism. These 
findings suggest that in response to the reductions in die-
tary carbohydrate and fat in the VLCD, there was selection 
for intestinal bacterial pathways related to the synthesis 
and metabolism of nutrients that were depleted.
Associations between changes in the plasma metabolome 
and the fecal microbiome
The intestinal microbiota, modulated by the gut environ-
ment, produces bioactive metabolites such as short-chain 
fatty acids and bile acids. The most abundant bacterial 
Post-WL
Pre-WL
a
Photosynthesis
Photosynthesis proteins
Cyanoaminoacid metabolism
Thiamine metabolism
Phenylpropanoid biosynthesis
Novobiocin biosynthesis
Bisphenol degradation
Base excision repair
Fatty acid biosynthesis
Glycerolipid metabolism
pyruvate metabolism
Pentose phosphate pathway
b
c
Fig. 3 Diet induced weight loss shows conservation of the core gut microbiome. a Principal coordinate analysis (PCoA) of microbiome variation in 
pre-(blue circles) and post-(red circles) weight loss samples based on unweighted UniFrac analysis. The red lines connect the pre- and post-weight 
loss samples for each subject. For each subject, the positions along PC1 and PC3 did not change pre- and post-weight loss, whereas PC2 increased. 
b Average UniFrac Distance within subjects (red) versus between subjects (blue). c Imputed characterization of VLCD-induced gut functional 
changes induced by weight loss, as determined by Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PICRUSt) 
analysis. Colors indicate imputed bacterial pathways that decrease (green) or increase (red) with weight loss
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taxa that decreased with the VLCD intervention were 
Faecalibacterium prausnitzii (PreWL 0.103 ± 0.023, 
PostWL 0.038 ± 0.017, p = 0.009) and genus Roseburia 
(PreWL 0.070 ± 0.027, PostWL 0.005 ± 0.003, p = 0.001) 
(Fig.  4a), which were negatively correlated with plasma 
BHB, a ketone body that is also a short chain fatty acid 
byproduct.
To further explore associations between gut microbiota 
and circulating metabolites following VLCD, we corre-
lated changes in the plasma metabolome and the fecal 
microbiome (Fig.  4b). Metabolomic pathways that were 
significantly altered as reported [9], were also correlated 
with significant changes in the fecal microbiota (Addi-
tional file  2). There were strong positive correlations 
between Catenibacterium and primary bile acid metabo-
lism (R = 0.82, p = 0.004), and Christensenellaceae;g__ 
with secondary bile acid metabolism (R = 0.68, p = 0.032). 
Purine metabolism pathways were strongly positively cor-
related with changes in Roseburia (R = 0.75, p = 0.018), 
Ruminococcus (R = 0.71, p = 0.027), and Oscillospira 
(R = 0.71, p = 0.027). We also observed negative correla-
tions of Erysipelotrichaceae;g__ in metabolite pathways 
involved with oxidative phosphorylation (R = − 0.81, 
p = 0.008), TCA cycle (R = − 0.67, p = 0.039) and inositol 
Fig. 4 Coordinated effects of VLCD-induced weight loss on the plasma metabolome and the fecal microbiome. a VLCD-induced weight loss is 
associated with changes in both selected fecal bacterial taxa and levels of plasma β-hydroxybutyrate. b Spearman correlation heat map for bacterial 
taxa (rows) versus plasma metabolites (columns) changing with weight loss at p-value < 0.1. Red denotes positive correlation (p < 0.1), dark red 
denotes strongly positive correlation (p < 0.05), blue denotes negative correlation (p < 0.1) while dark blue denotes strongly negative correlation 
(p < 0.05). c Spearman correlation bubble plot of total fecal microbiota versus selected plasma metabolite pathways
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metabolism (R = − 0.70, p = 0.031) in response to the 
VLCD weight loss. Xanthine metabolism was positively 
correlated with Ruminococcus (R = 0.67, p = 0.039).
We next sought to analyze the relative impact of the 
fecal microbiome in determining changes in circulat-
ing metabolites and metabolite pathways (Fig.  4c). We 
selected the metabolite BHB, which showed the largest 
increase in plasma PostWL, and two pathways involv-
ing the metabolism of biologically active intermediaries 
(xanthine and secondary bile acids) for correlation analy-
sis with differentially changed bacterial taxa. The micro-
biota has greater impact on the metabolite 3BHB and 
the xanthine metabolism pathway than on the second-
ary bile acid metabolism pathway. The strong increase in 
plasma 3BHB was predominantly associated with posi-
tive changes in Roseburia and Akkermansia.
Effects of the VLCD‑induced weight loss on bile acids
Since obesity is accompanied by fecal bile acid com-
position changes [15], we evaluated the effects of the 
VLCD-induced weight loss on the content and com-
position of fecal bile acids. Total fecal bile acid levels 
decreased by 26% after the intervention (Fig.  5a). Most 
(> 95%) fecal bile acids were unconjugated in both pre- 
and post-study samples. Approximately 50% deoxycholic 
acid (DCA) and ~ 40% of lithocholic acid (LCA) spe-
cies were observed at baseline, and the mean percent of 
both DCA and LCA fell markedly after weight loss. They 
were partially replaced by increased primary (cholic 
and chenodeoxycholic) bile acids, suggesting reduction 
in bacterial deconjugation and subsequent oxidative 
enzymatic modification (Table 1). However, the distribu-
tion of these bile acids in the feces of individual subjects 
varied markedly, and changes were not significant.
Following weight loss, plasma bile acids showed an 
8.7-fold increase in glycolithocholic acid and > threefold 
increase in taurolithocholic acids, with a twofold reduc-
tion in the cholic acid (Additional file 1: Table S1). Plasma 
FGF19 levels were variable and did not significantly 
change following VLCD-induced weight loss (PreWL 
162 ± 39 pg/mL, PostWL 187 ± 53 pg/mL, p = NS).
Associations between changes in fecal bile acids 
and the microbiome
The microbiota and bile acids in the gut lumen have 
reciprocal compositional effects [37]. We therefore 
examined bacterial taxa and individual bile acids 
in feces. We observed a strong negative correlation 
between Clostridiaceae;g__ (unknown genus) and LCA 
(Fig.  5b; R = − 0.82, p = 0.004) (Table  1), but strong 
positive correlations between Eubacterium and LCA 
(R = 0.82, p = 0.007), isolithocholic acid (R = 0.78, 
p = 0.012). There was also a strong positive correla-
tion between Oscillospira with cholic acid (R = 0.660, 
p = 0.044). Isolithocholic correlated negatively with 
Clostridiaceae;g__ (R = − 0.706, p = 0.023) and Rumi-
nococcus (R = − 0.78, p = 0.012). Taxa Faecalibacterium 
showed strong positive correlations with ursodeoxy-
cholic acid (R = 0.72, p = 0.024) and murocholic acid 
(R = 0.67, p = 0.03). The observed bile acid changes 
point to possible bacterial-metabolite interactions with 
potential endocrine effects.
Fig. 5 Coordinated effects of VLCD on fecal bile acids and microbiota. a Changes in total bile acids in feces following VLCD-induced weight loss 
(mean ± SE, *p < 0.05). b Spearman correlation heat map for bacterial taxa (rows) versus fecal bile acids (columns) changing with weight loss, at 
p-value < 0.1. Red denotes positive correlation (p < 0.1), dark red denotes strongly positive correlation (p < 0.05), blue denotes negative correlation 
(p < 0.1) while dark blue denotes strongly negative correlation (p < 0.05)
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Associations between changes in fecal bile acids 
and plasma metabolites
Bile acids in the gastrointestinal tract can alter circulating 
metabolites affecting glucose and lipid metabolism and 
homeostasis. These metabolic effects may occur directly 
through the action of circulating bile acids or indirectly 
through activation of receptors in the small or large intes-
tine. We analyzed correlations between changes in circu-
lating plasma metabolic pathways and changes in fecal 
bile acids (Fig.  6a). LCA correlated most strongly with 
the metabolic pathway for alanine and aspartate metabo-
lism (R = 0.82, p = 0.007). The LCA species, lithocholic 
and isolithocholic acids, correlated positively with the 
metabolism of amino acids glycine, serine, and threonine 
(R = 0.672, p = 0.039; R = 0.6, p = 0.073, respectively). 
There was a positive correlation between purine meta-
bolic pathways and ursocholic (R = 0.770, p = 0.014) and 
cholic (R = 0.721, p = 0.024) acids. Conversely, several bile 
acids correlated negatively with fatty acid monohydroxy-
late metabolism including glycoursodeoxycholic acid 
(R = − 0.85, p = 0.006), 5-β cholanic acid (R = − 0.610, 
p = 0.066) and DCA (R = − 0.610, p = 0.066). Strong 
negative correlations were found between xanthine 
pathway metabolites and LCA (R = − 0.781, p = 0.012). 
Sphingolipid metabolites also showed a strong negative 
correlation with 12-ketodeoxycholic acid (R =  − 0.794, 
p = 0.010). Secondary bile acid metabolism pathways, 
encompassing most circulating bile acids, correlated pos-
itively with fecal bile acids 5-β cholanic acid (R = 0.806, 
p = 0.008), 12-ketodeoxycholic acid (R = 0.660, p = 0.044) 
and, to a lesser extent, glycochenodeoxycholic acid 
(R = 0.563, p = 0.096). The concentration of fecal short 
chain fatty acids measured by GC–MS were quite low 
before the start of the VLCD and remained low there-
after (acetate 5 ± 3  mM, butyrate 1 ± 4  mM, propionate 
6 ± 15  mM). A bubble plot illustrating the relative cor-
relation of fecal bile acids with these selected plasma 
metabolites (Fig. 6b) shows a relationship with secondary 
bile acid metabolism. Similarly little effects on BHB and 
xanthine metabolism were observed.
Association between fecal bile acids and the adipose tissue 
transcriptome
We previously reported several metabolic changes in 
the white adipose tissue (WAT) transcriptome follow-
ing VLCD-induced weight loss [9]. Correlation analysis 
with the newly presented fecal bile acid data shows WAT 
mitogen-activated protein (MAP) kinase gene expression 
negatively correlated with fecal glycochenodeoxycholic 
acid (R = − 0.66, p = 0.044; Fig.  7a). Other relation-
ships of functional significance were the positive corre-
lations between 12-deoxyketocholic acid and pathways 
for receptor signaling protein serine threonine kinase 
(R = 0.76, p = 0.016) and for cell cortex (R = − 0.70, 
p = 0.031). We also observed strongly positive correla-
tions between 3 fecal bile acids (DCA and its metabolites, 
5-β-cholanic and 12-ketodeoxycholic acids) and adipose 
tissue cell cortex genes (p < 0.05). Fecal microbiota also 
showed striking positive correlations with several gene 
expression pathways in adipose tissue including protein 
Table 1 Composition of fecal bile acids detected by UPLC–MS (abundance)
Abundance is presented a counts from UPLC–MS analysis in fecal specimens
PreWL preweight loss, PostWL post weight loss, BA bile acid
PreWL Percent PostWL Percent Paired T test
Conjugated BA
 Taurocholic 76 90
 Taurochenodeoxycholic 21 61
 Glycochenodeoxycholic 74 344
 Glycoursocholic 13 127
 Glycolithocholic 32 8
Total conjugated BA 216 1.2 620 4.8 0.08
Unconjugated BA
 Lithocholic 5573 30.6 2372 18.4 0.11
 Isolithocholic 1399 7.7 7.2 5.5 0.14
 Muricholic + 3-β-muricholic 114 0.6 66 0.5 0.47
 Cholic 1049 5.8 3796 29.5 0.47
 Deoxycholic 9306 51.1 4721 36.7 0.07
 Ursocholic 565 3.1 550 4.3 0.97
Total unconjugated BA 18,222 98.8 12,847 95.5 0.07
Total bile acids 18,625 100 13,786 100 0.02
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amino acid n-linked glycosylation (p < 0.005) (Fig.  7b). 
Peptostreptococcaceae;g__ was correlated negatively 
with the JNK cascade and stress activated protein kinase 
signaling pathways in adipose tissue (each p < 0.005). 
These results allow for further exploration of connections 
between intestinal contents and distant organs such as 
Fig. 6 Coordinated effects of VLCD-induced weight loss on fecal bile acids and the plasma metabolome. a Spearman correlation heat map for 
plasma metabolites (rows) versus stool bile acids (columns) changing with weight loss at p-value < 0.1. Red denotes positive correlation (p < 0.1), 
dark red denotes strongly positive correlation (p < 0.05), blue denotes negative correlation (p < 0.1) while dark blue denotes strongly negative 
correlation (p < 0.05). b Spearman correlation bubble plot of total fecal bile acids versus selected plasma metabolite pathways
Page 12 of 17Alemán et al. J Transl Med  (2018) 16:244 
adipose tissue and should contribute to a better under-
standing of metabolic diseases.
Discussion
The present study aimed to determine the effects of rapid 
weight loss induced by a VLCD on concomitant changes 
in fecal microbiota and bile acid content and composi-
tion. We also sought to characterize their relationship 
with the plasma metabolome and adipose tissue tran-
scriptome. Urinary metabolomic profiles confirmed that 
starvation ketosis and protein sparing occurred during 
this intervention as well as a modulation of the func-
tional status of the microbiome [38]. We show that the 
core microbiota was preserved during VLCD-induced 
weight loss, but we also found changes in several groups 
of bacterial taxa with functional implications. In paral-
lel, fecal bile acid content fell, with a trend to increased 
fecal conjugated bile acids and reduced deoxycholic acid. 
These changes correlated with changes in plasma metab-
olites and adipose tissue gene expression and imply that 
changes in the fecal microbiome participate in many of 
the benefits of weight reduction.
Gut bacteria play an important role in metabolic health 
and metabolic homeostasis [39]. The fecal microbiota in 
baseline specimens differed markedly between the study 
subjects. However, despite consuming an identical VLCD 
diet in both composition and quantity, the fecal micro-
biota among the study subjects did not become more 
similar. Their individual core microbiome was preserved, 
and microbial richness was not reduced. A low microbial 
richness has been described in obese subjects with com-
plications [10] and is reversible with a low calorie diet 
[40]. We did not observe these findings, possibly due to 
the population studied which was comprised of obese 
postmenopausal women with relatively few complica-
tions of their disease. Our data are consistent with obser-
vations that an abrupt but modest early change in fecal 
microbiota composition occurs shortly after a switch in 
diet, which reverted back toward the baseline microbiota 
following longer-term feeding of the new diet [41]. It is 
possible that assessment of the fecal microbiota earlier in 
VLCD-induced weight loss might have shown different 
results.
Due to our study design, changes attributable to 
weight loss versus diet change cannot be distinguished. 
Reports on the effects of diet-induced weight loss on 
the fecal microbiome have been mixed: some stud-
ies have shown conservation [42], while others report 
shifts [43] in the core microbiome. In contrast, bariat-
ric surgery-induced weight loss is accompanied by dra-
matic shifts in microbiome composition, which might 
reflect both changes in gastrointestinal anatomy as well 
as nutrient effects [17].
We found several specific changes in the fecal micro-
biome that could have importantly affected systemic 
metabolism. In our study, Christensenellaceae;g__ 
(unknown genus) was relatively enriched between 
study start and study end. Christensenella is associated 
with healthy BMI, reduces diet-induced weight gain in 
mice, and is receiving lots of attention as a potentially 
Fig. 7 Coordinated effects of VLCD-induced weight loss on the fecal compartment and the adipose tissue transcriptome. a Spearman correlation 
heat map for adipose tissue transcriptome pathways (rows) versus fecal bile acids (columns) changing with weight loss, at p-value < 0.1. Red 
denotes positive correlation (p < 0.1), dark red denotes strongly positive correlation (p < 0.05), blue denotes negative correlation (p < 0.1) while 
dark blue denotes strongly negative correlation (p < 0.05). b Spearman correlation heat map for fecal microbiota taxa (rows) versus adipose tissue 
transcriptome pathways (columns) changing with weight loss, at p-value < 0.1. Red denotes positive correlation (p < 0.1), dark red denotes strongly 
positive correlation (p < 0.05), blue denotes negative correlation (p < 0.1) while dark blue denotes strongly negative correlation (p < 0.05)
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heritable member of the microbiome [44]. It is surpris-
ing that in our study this bacterial genus belonging to 
Christensenellaceae negatively associated with weight 
loss and may be a potentially important finding. Any 
role of this genus in weight management may be more 
complex than we appreciate from cross-sectional stud-
ies. Prior studies have examined weight associations 
with this genus in obesity [45, 46] but do not associate 
it with weight loss, especially in very obese patients. On 
the other hand, Faecalibacterium prausnitzii decreased 
in our study, but has been proposed as a microbial 
discriminant between gut disorders as ulcerative coli-
tis and Crohn’s disease [47]. There was no consistent 
increase in Akkermansia, as had been described [41]. 
Our subjects were very obese without complications, 
yet showed a reduced Bacteroides:Firmicutes ratio, 
which was unchanged by the VLCD. Our observation 
contrasts with prior studies [11, 42], indicating that this 
reduced ratio and its responsiveness to caloric restric-
tion are not universal phenomena.
PICRUSt-imputed metagenomic functional analy-
sis showed changes that may signify a response of the 
fecal microbiome toward increased carbohydrate and 
lipid metabolism following the intervention. The VLCD 
is severely restricted in carbohydrates and lipids, which 
should decrease the amounts of these nutrients enter-
ing the colon. Our analysis suggests that the microbiota 
may compensate for the lack of substrates in the diet by 
increasing their production of these carbohydrates and 
lipids following the VLCD [48]. Recent studies show that 
the quality of food rather than caloric content is the key 
for maintaining rich/healthy fecal microbiome [14, 49]. 
Although others observed changes in fecal SCFA con-
tent following VLCD-induced weight loss, as has recently 
been reported [42], these changes presumably reflect the 
lack of fermentable fiber in the colon.
Altered increased bile acid synthesis and transport has 
been reported to occur in obesity [15], and in our study 
total fecal bile acids decreased significantly following the 
VLCD. This decrease could result from lower hepatic bile 
acid synthesis and/or bile acid fractional turnover [50]. 
Fat-free diets reduce bile acid synthesis rates in humans 
[50] and have been shown to decrease fractional bile acid 
turnover in the rat [51] so that VLCD-induced decrease 
in fecal bile acids likely was due to both factors. In addi-
tion, VLCD feeding has been associated with reduced gall 
bladder emptying [52], which can contribute to increased 
gallstone formation that has been observed with this 
diet [53]. As expected, most fecal bile acids in our study 
were unconjugated with predominant LCA species. LCA 
is formed from chenodeoxycholic acid in the terminal 
ileum and colon mainly by the highly abundant genus 
Clostridium [54]. Although LCA has also been described 
to increase with caloric restriction [55] this did not occur 
after the VLCD in our study.
Bile acids interact with several receptors in gut epithe-
lial cells [56], which induce metabolic effects in the intes-
tine and the liver [19, 57]. Primary bile acids function 
as natural ligands for the gut nuclear receptor farnesoid 
X receptor (FXR) and secondary bile acids are ligands 
for the G protein coupled intestinal plasma membrane 
receptor TGR5. Activation of these receptors by bile 
acids can alter lipid [58], glucose [59], and energy homeo-
stasis [60]. FXR inhibition improves obesity related meta-
bolic dysfunction including insulin resistance [61]. In the 
mouse, microbial reduction of tauro-β-muricholic acid 
regulates ileal FGF15 concentrations and inhibits hepatic 
bile acid synthesis [62], illustrating the profound effect of 
the gut microbiota on bile acid metabolism. In addition, 
bile acid responsive receptors as well as bile acids [52] 
are found outside the enterohepatic circulation, includ-
ing the kidney and heart [63]. The major elevation of fast-
ing plasma levels of glycolithocholic and taurolithocholic 
sulfate that occurred after the intervention in our study 
may have interacted with such receptors to alter cellular 
metabolic functions. Gut bile acids activate FXR, which 
induces expression of FGF19 in humans [64]. Plasma 
FGF19 levels varied widely between subjects in our study, 
as previously reported [65] and in line with the between-
subject variation in core fecal microbiome. Overall, our 
data suggest that VLCD-induced changes in circulat-
ing bile acid levels contribute to the beneficial effects of 
weight loss despite large variation between subjects.
Our weight loss regimen greatly impacted the meta-
bolic homeostasis of our subjects as judged by its 
effects on fasting plasma metabolites [9]. Urinary 
metabolite abundance, which mirror starvation keto-
sis and decreased muscle protein catabolism, showed 
expected changes suggestive of muscle sparing. These 
metabolite changes could result from direct effects on 
the liver and internal organs or might reflect changes in 
gut microbiota or bile acids. Our data showed promi-
nent increases in urinary as well as plasma content of 
4CS, a microbial breakdown product of tyrosine and 
phenylalanine, to 4-hydroxyphenylacetate. This sug-
gests greater availability of the precursors tyrosine 
and phenylalanine for fecal microbial metabolism. The 
presence of this microbial-derived metabolite implies 
additional crosstalk between amino acid absorption 
from the gut microbiota and its metabolism in the liver. 
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Additionally, we observed decreased plasma abundance 
and urinary excretion of TMAO, which likely reflects 
the decrease in dietary red meat intake.
The branched chain amino acids (BCAAs) leucine, 
isoleucine, and valine are early biomarkers of insu-
lin resistance with possible pathophysiologic roles 
in glucose intolerance and muscle insulin resistance 
[66, 67]. Changes in the levels of these BCAAs could 
be due to alterations in microbiota. We observed 
decreases in plasma levels of the BCAAs, tyrosine, 
and phenylalanine levels along with increases in urine 
isoleucine, 3-methyl-2-oxovalerate, and 3-hydroxy-
valerate excretion. Plasma BCAA metabolism showed 
a trend toward a negative correlation with the fecal 
taxa Lachnospiraceae;g__ and Coprococcus. A recent 
European report also associated Prevotella copri with 
increased circulating BCAA levels in insulin resistance 
[18]. Bacteroides thetaiotaomicron has been linked 
to changes in BCAAs accompanying improved insu-
lin resistance with weight loss [22]. However, these 
taxa were not in our top 20 differentially changed 
microbiota taxa. The TCA cycle metabolite citrate 
increased in plasma, whereas both urinary citrate 
and succinate levels decreased following the VLCD. 
Erysipelotrichaceae;g__ correlated with TCA cycle and 
oxidative phosphorylation metabolite pathways.
Since microbiota and bile acids mutually interact in 
the gut, it is not surprising that we found highly sig-
nificant positive correlations between plasma bile acid 
metabolism and fecal microbiota including Catenibac-
terium and Christensenellaceae;g__. Catenibacterium 
was enriched in subjects with improved CVD risk in the 
Bogalusa Heart Study [68]. Christensenellaceae has been 
associated with lower BMI [44]. Roseburia and Rumino-
coccus strongly correlated with plasma purine pathway 
metabolism. At the same time, Ruminococcus as well as 
Christensenellaceae;g__ showed a positive correlation 
with xanthine metabolism, a pathway through which 
adenosine, adenine, and inositol are shunted into uric 
acid formation. Despite these microbial alterations, no 
difference was observed in plasma uric acid post VLCD-
induced weight loss.
Plasma levels of BHB increased markedly after the 
intervention. This likely reflects systemic lipid metabo-
lism, but could in part also result from less catabolism 
by Faecalibacterium prausnitzii and Roseburia. These 
organisms were negatively correlated with plasma BHB 
concentrations. Since conjugated bile acids activate FXR 
receptors expressed in adipose tissue [69], we further 
explored correlations between fecal bile acids (and fecal 
microbiota) and changes in WAT gene expression path-
ways. Serine threonine kinase, with its receptor, initi-
ates the catabolism of ATP and participates in several 
metabolic pathways including MAP kinase signaling [70]. 
Therefore, the positive correlation between fecal 12-keto-
cholic acid and serine threonine receptor signaling sug-
gests a functional effect. MAP kinase pathway gene 
expression also correlated with several fecal bile acids.
Conclusion
VLCD-induced weight loss was used to obtain novel 
data on the changes in weight, microbiome, plasma and 
urinary metabolites, and adipose gene expression in 
humans. Though analysis of our clinical study was correl-
ative, such information is essential to define the causes of 
many of the beneficial effects of weight loss. The strengths 
of the present study were that the environment and exer-
cise for our subjects were carefully maintained and moni-
tored, the diet was identical, and the degree of weight loss 
very similar. One weakness was that we studied only 10 
subjects, so the associations need confirmation in model 
organisms or larger clinical studies. Pairwise correlations 
used in this study are limited in establishing causality 
for the observed associations. Another limitation of this 
study is the lack of fecal metabolite measurements. Due 
to feasibility considerations we did not include a weight 
neutral cohort to compare, but we previously reported on 
the stability of fecal microbiota following celecoxib treat-
ment in a weight neutral study [34]. In summary, VLCD-
induced weight loss modulated the fecal microbiome in 
functionally important ways to compensate for the lack of 
nutrients, with concomitant decreases in total fecal bile 
acids and most unconjugated species detected. Moreover, 
we show that some changes induced by the microbiome 
are likely to alter systemic metabolism, and have identi-
fied others that occur but do not correlate with either adi-
pose or metabolite changes as outlined in Fig. 8. We posit 
the metabolic changes occurring in the host with caloric 
restriction and 10% weight loss, namely ketogenesis and 
free fatty acid production, have a profound systemic 
effects directly through metabolic hormonal signals and 
indirectly by inducing microbiota-related changes that 
signal through their own metabolites. Using a very con-
trolled diet in a metabolic ward, we show diet specific 
changes in the fecal microbiome and fecal bile acid pro-
file. By providing an intervention model that associates 
related compartments such as the fecal microbiota and 
fecal bile acids with distant compartments such as the 
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plasma metabolome and subcutaneous adipose tissue, we 
propose a novel approach to the study of the biology of 
human weight loss.
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